Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

The old belief that testosterone therapy increases prostate cancer or makes it worse is no longer backed up by modern ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Early-stage prostate cancer is very treatable with surgery and radiation therapy. Once the cancer spreads, it becomes harder to stop. Late-stage prostate cancer treatments like chemotherapy and ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first line of treatment is often hormone therapy, which is very good at slowing or stopping the cancer — ...

Men’s Health Thailand by Dr. Niti Navanimitkul For many men, a diagnosis of prostate cancer comes with two major worries: “How serious is my cancer?” and “Will the treatment change my quality of life?